The Greater Cannabis Company, Inc. (GCAN) 10-Q 19 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 19, 2020
Cover [Abstract]
Entity Registrant Name	Greater Cannabis Company, Inc.
Entity Central Index Key	0001695473
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		332,089,081
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash	$ 178,632	$ 24,662
Advance to supplier		28,000
Note receivable	23,575
Total current assets	202,207	52,662
OTHER ASSETS
Right of first refusal agreement cost (less accumulated amortization of $ 3,333 and $ 0)	21,667
Total assets	223,874	52,662
CURRENT LIABILITIES
Accounts payable	6,963	17,517
Accrued interest	12,478	20,619
Accrued salaries	136,000	98,000
Accrued royalties		50,000
Advance from customer		27,977
Loans payable to related parties	260,000	260,000
Notes payable to third parties (less debt discounts of 145,449 and $505,937 respectively)	183,820	399,318
Derivative liability	325,935	725,865
Total current liabilities and total liabilities	925,196	1,599,296
STOCKHOLDERS' (DEFICIENCY)
Common stock; 500,000,000 shares authorized, $.001 par value, as of September 30, 2020 and December 31, 2019, there are 203,627,370 and 39,301,323 shares outstanding, respectively	203,627	39,301
Additional paid-in capital	2,033,257	783,891
Accumulated deficit	(2,947,618)	(2,379,238)
Total stockholders' (deficiency)	(701,322)	(1,546,634)
Total liabilities and stockholders' (deficiency)	223,874	52,662
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value:	9,412	9,412
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value:

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Right of first refusal agreement	$ 3,333	$ 0
Debt discount	$ 145,449	$ 505,937
Preferred stock, shares authorized	19,000,000	19,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares outstanding	203,627,370	39,301,323
Series A Convertible Preferred Stock [Member]
Preferred stock, shares issued	9,411,998	9,411,998
Preferred stock, shares outstanding	9,411,998	9,411,998
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Total revenue		$ 2,620	$ 48,044	$ 2,620
Gross profit (loss)			(46)	2,620
Operating Expenses:
Officers compensation	51,000	51,000	153,000	153,000
Amortization of Pharmedica Exclusive License Agreement cost		5,000		15,000
Amortization of Right of First Refusal Agreement cost	1,250		3,333
Other operating expenses (including stock-based consulting fees of $0, $12,250, $0 and $88,130 , respectively)	18,675	25,059	84,546	165,213
Total operating expenses	70,925	81,059	240,879	333,213
Income (loss) from operations	(70,925)	(78,439)	(240,925)	(330,593)
Other income (expenses):
Income (expense) from derivative liability	213,751		909,596	194,551
Loss on conversions of notes payable	(467,555)	24,035	(829,342)	(230,839)
Gain from Surrender Agreement with Emet Capital Partners, LLC			472,170
Forgiveness of royalty payable	50,000		50,000
Interest expense	(6,251)	(3,972)	(59,726)	(14,592)
Amortization of debt discounts	(178,280)	(68,054)	(870,153)	(171,085)
Total other income (expenses)	(388,335)	(47,991)	(327,455)	(221,965)
Income (loss) before provision for income taxes	(459,260)	(126,430)	(568,380)	(552,558)
Provision for income taxes
Net income (loss)	$ (459,260)	$ (126,430)	$ (568,380)	$ (552,558)
Basic and diluted income (loss) per common share	$ (.00)	$ 0	$ (0.01)	$ (0.02)
Weighted average common shares outstanding-basic and diluted	130,367,164	35,359,983	84,172,283	34,439,921
Product Sales [Member]
Revenue:
Total revenue			$ 48,044
Cost of product sales			48,090
Consulting Fees [Member]
Revenue:
Total revenue		$ 2,620		$ 2,620

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Stock-based consulting fees	$ 0	$ 12,250		$ 88,130

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Series A Preferred Stock [Member]
Beginning Balance	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412
Beginning Balance, shares	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversions of note payable and accrued interest into shares of common stock
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Issuance of 542,000 common shares for consulting services rendered
Issuance of 175,000 common shares for professional services rendered
Net loss
Ending Balance	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412
Ending Balance, shares	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998
Series B Preferred Stock [Member]
Beginning Balance				$ 9,000	$ 9,000
Beginning Balance, shares				9,000,000	9,000,000
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversions of note payable and accrued interest into shares of common stock
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019						$ 9,000
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019, shares						9,000,000
Issuance of 542,000 common shares for consulting services rendered
Issuance of 175,000 common shares for professional services rendered
Net loss
Ending Balance				$ 9,000	$ 9,000	$ 9,000		$ 9,000
Ending Balance, shares				9,000,000	9,000,000	9,000,000		9,000,000
Common Stock [Member]
Beginning Balance	$ 88,350	$ 60,786	$ 39,301	$ 35,272	$ 33,346	$ 31,881	$ 39,301	$ 31,881
Beginning Balance, shares	88,349,536	60,786,011	39,301,323	35,272,483	33,345,883	31,880,969	39,301,323	31,880,969
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversions of note payable and accrued interest into shares of common stock	$ 115,277	$ 27,564	$ 21,485			$ 770
Conversions of note payable and accrued interest into shares of common stock, shares	115,277,834	27,563,525	21,484,688			769,785
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019						$ 695
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019, shares						695,129
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Issuance of 175,000 common shares for professional services rendered				$ 175
Issuance of 175,000 common shares for professional services rendered, shares				175,000
Net loss
Ending Balance	$ 203,627	$ 88,350	$ 60,786	$ 35,447	$ 35,272	$ 33,346	$ 203,627	$ 35,447
Ending Balance, shares	203,627,370	88,349,536	60,786,011	35,447,483	35,272,483	33,345,883	203,627,370	35,447,483
Additional Paid in Capital [Member]
Beginning Balance	$ 1,351,467	$ 1,168,499	$ 783,891	$ 577,550	$ 323,598	$ 233,991	$ 783,891	$ 233,991
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversions of note payable and accrued interest into shares of common stock	681,790	182,968	384,608		178,614	99,302
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019						(695)
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019						(9,000)
Issuance of 542,000 common shares for consulting services rendered					75,338
Issuance of 175,000 common shares for professional services rendered				12,075
Net loss
Ending Balance	2,033,257	1,351,467	1,168,499	589,625	577,550	323,598	2,033,257	589,625
Accumulated Deficit [Member]
Beginning Balance	(2,488,358)	(3,590,807)	(2,379,238)	(1,156,771)	(868,992)	(839,070)	(2,379,238)	(839,070)
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019						108,427
Conversions of note payable and accrued interest into shares of common stock
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Issuance of 542,000 common shares for consulting services rendered
Issuance of 175,000 common shares for professional services rendered
Net loss	(459,260)	1,102,449	(1,211,569)	(126,430)	(287,779)	(138,349)
Ending Balance	(2,947,618)	(2,488,358)	(3,590,807)	(1,283,201)	(1,156,771)	(868,992)	(2,947,618)	(1,283,201)
Beginning Balance	(1,039,129)	(2,352,110)	(1,546,634)	(525,537)	(493,636)	(563,786)	(1,546,634)	(563,786)
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019						108,427
Conversions of note payable and accrued interest into shares of common stock	797,067	210,532	406,093		179,998	100,072
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Issuance of 542,000 common shares for consulting services rendered					75,880
Issuance of 175,000 common shares for professional services rendered				$ 12,250
Issuance of 175,000 common shares for professional services rendered, shares				175,000
Net loss	(459,260)	1,102,449	(1,211,569)	$ (126,430)	(287,779)	(138,349)	(568,380)	(552,558)
Ending Balance	$ (701,322)	$ (1,039,129)	$ (2,352,110)	$ (639,717)	$ (525,537)	$ (493,636)	$ (701,322)	$ (639,717)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficiency (Unaudited) (Parenthetical) - USD ($)	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Apr. 16, 2019	Feb. 14, 2019	Jan. 04, 2019	Mar. 10, 2017	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019
Conversion of note payable				$ 40,500		$ 670		$ 311,050	$ 67,082	$ 165,350
Accrued interest	$ 515	$ 4,015	$ 2,680	$ 7,961		$ 100		$ 18,462	$ 10,613	$ 11,793
Debt conversion converted shares issued	637,273	1,468,204	1,748,363	1,384,600		769,785		115,277,834	27,563,525	21,484,688
Debt conversion of shares, value	$ 10,000	$ 29,000	$ 53,705	$ 179,998		$ 100,072		$ 797,067	$ 210,532	$ 406,093
Exercise of warrants						1,400
Issuance of common stock in cashless exercise transaction, shares						695,129	26,905,969
Exchange of warrants					438,600
Issuance of common shares for professional services											175,000
Class B Convertible Preferred Stock [Member]
Conversion of convertible preferred stock					9,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
OPERATING ACTIVITIES
Net income (loss)	$ (459,260)	$ (568,380)	$ (552,558)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:
Loss on conversions of notes payable and accrued interest to common stock		829,342	230,839
Gain from Surrender Agreement with Emet Capital Partners, LLC		(472,170)
Stock-based professional fees			88,130
Forgiveness of royalty payable	(50,000)	(50,000)
(Income) expense from derivative liability	(213,751)	(909,596)	(194,551)
Amortization of Pharmedica Exclusive License Agreement cost			15,000
Amortization of Right of First Refusal Agreement cost	1,250	3,333
Amortization of debt discounts	178,280	870,153	171,085
Changes in operating assets and liabilities:
Advance to supplier		28,000
Note receivable		(23,575)
Accounts payable		(10,554)	(8,190)
Accrued interest		32,726	14,202
Accrued salaries		38,000	(28,000)
Advance from customer		(27,977)
Net cash used in operating activities		(260,698)	(264,043)
INVESTING ACTIVITIES
Purchase of Right of First Refusal Agreement		(25,000)
Net cash used in investing activities		(25,000)
FINANCING ACTIVITIES
Amount paid in connection with Surrender Agreement with Emet Capital Partners, LLC		(70,000)
Proceeds from notes payable to third parties		509,668	250,000
Net cash provided by financing activities		439,668	250,000
NET INCREASE (DECREASE) IN CASH		153,970	(14,043)
CASH BALANCE, BEGINNING OF PERIOD		24,662	59,891
CASH BALANCE, END OF PERIOD	$ 178,632	178,632	45,848
Supplemental Disclosures of Cash Flow Information:
Interest paid
Income tax paid
Non-cash Investing and Financing Activities:
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $ 100,072) on January 4, 2019			100,072
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019			695
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019			9,000
Initial derivative liability charged to debt discounts		509,667	250,000
Conversions of notes payable ($165,350) and accrued interest ($11,793) into 21,484,688 shares of common stock (Fair Value of $ 406,093) for the three months ended March 31, 2020		406,093
Conversions of notes payable ($ 40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $ 179,998) on April 16, 2019			179,998
Conversions of notes payable ($ 67,082) and accrued interest ($10,613) into 27,563,525 shares of common stock (Fair Value of $ 210,532) for the three months ended June 30, 2020		210,532
Conversions of notes payable ($ 311,050) and accrued interest ($18,462) into 115,277,834 shares of common stock (Fair Value of $ 797,067) for the three months ended September 30, 2020		$ 797,067

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Apr. 16, 2019	Feb. 14, 2019	Jan. 04, 2019	Mar. 10, 2017	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Conversion of note payable				$ 40,500		$ 670		$ 311,050	$ 67,082	$ 165,350
Accrued interest	$ 515	$ 4,015	$ 2,680	$ 7,961		$ 100		$ 18,462	$ 10,613	$ 11,793
Debt conversion converted shares issued	637,273	1,468,204	1,748,363	1,384,600		769,785		115,277,834	27,563,525	21,484,688
Debt conversion of shares, value	$ 10,000	$ 29,000	$ 53,705	$ 179,998		$ 100,072		$ 797,067	$ 210,532	$ 406,093
Exercise of warrants						1,400
Issuance of common stock in cashless exercise transaction, shares						695,129	26,905,969
Exchange of warrants					438,600
Class B Convertible Preferred Stock [Member]
Conversion of convertible preferred stock					9,000,000

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately 94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). The Company’s business plan is to (i) commercialize its ETP technology and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiaries Green C Corporation and Biocanrx Inc. Interim Financial Statements The interim financial statements as of September 30, 2020 and for the three and nne months ended September 30, 2020 and 2019 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of results that may be expected for the year ending December 31, 2020. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2019 as included in our report on Form 10-K. Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no cash equivalents. Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of September 30, 2020, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods. Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values. Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. Revenue Recognition Revenue from product sales will be recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) the price is fixed or determinable, (3) collectability is reasonably assured, and (4) delivery has occurred. Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs. Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note G), shares relating to convertible notes payable to third parties (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES see NOTE G - CAPITAL STOCK AND WARRANTS Recently Enacted Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all prior revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under prior U.S. GAAP. As amended by the FASB in July 2015, the standard became effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 has had no impact on our Financial statements for the periods presented. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-08 has had no impact on our Financial statements for the periods presentd. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-10 has had no impact on our financial statements for the periods presented. On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance became effective for annual periods beginning after December 15, 2018. Accordingly, effective January 1, 2019, the Company reduced the derivative liability of warrants with “down round” features (and do not contain variable conversion features) of $108,427 at December 31, 2018 to $0 and recognized a $108,427 cumulative effect adjustment reduction of accumulated deficit.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE B - GOING CONCERN Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future obligations as they become due within one year after the date the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued. In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. As of September 30 2020, the Company had cash of $178,632, total current liabilities of $925,196 and negative working capital of $722,989. For the nine months ended September 30, 2020, we incurred a net loss of $568,380 and used $260,698 cash from operating activities. We expect to continue to incur negative cash flows until such time as our business generates sufficient cash inflows to finance our operations and debt service requirements. In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources. There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing shareholders. We have therefore concluded there is substantial doubt about our ability to continue as a going concern through November 2021. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty related to our ability to continue as a going concern.

Right of First Refusal Agreemen

Right of First Refusal Agreement	9 Months Ended
	Sep. 30, 2020
Right Of First Refusal Agreement
Right of First Refusal Agreement	NOTE C – RIGHT OF FIRST REFUSAL AGREEMENT On January 30, 2020, the Company executed a Right of First Refusal Agreement with an entity engaged in the business of cosmetics, health, and well-being (“KTV”). The Agreement provided for the Company to pay KTV $25,000 on January 30, 2020 (which was paid January 30,2020) and to make other investments in opportunities to be pursued by KTV and/or payments to KTV to enable KTV to pursue and secure Cannabidiol (“CBD”) opportunities. The Agreement provides the Company an exclusive right of first refusal to participate in all CBD opportunities to be pursued by KTV for a term of five years. The $25,000 cost for this Agreement is being amortized over the five year term of the Agreement.

Loans Payable to Related Partie

Loans Payable to Related Parties	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Loans Payable to Related Parties	NOTE D - LOANS PAYABLE TO RELATED PARTIES Loans payable to related parties consist of: September 30, December 31, Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock 80,000 80,000 Total $ 260,000 $ 260,000 Pursuant to loan and contribution agreements dated July 31, 2018, the above loans are non-interest bearing and are to be repaid after the Company raises from investors no less than $1,500,000 or generates sufficient revenue to make repayments (each, a “Replacement Event”). If the First Replacement Event does not occur within 18 months from July 31, 2018, the loans are to be repaid immediately. In the event there is insufficient capital to repay the loan, the lenders have the option to convert all or part of the loans into shares at the Company common stock at the average trading price of the 10 days prior to the date of the conversion request.

Notes Payable to Third Parties

Notes Payable to Third Parties	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Notes Payable to Third Parties	NOTE E - NOTES PAYABLE TO THIRD PARTIES Notes payable to third parties consist of: September 30, 2020 December 31, 2019 Allonge to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 $ - $ 2,420 Allonge 2 to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 - 1,100 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share. 375 375 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due February 12, 2020-less unamortized debt discount of $ 0 and $ 33,396, respectively (i) - 250,082 Convertible Promissory Note dated January 27, 2020 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due January 27, 2021-less unamortized debt discount of $36,883 and $ 0, respectively (i) 76,245 - Convertible Promissory Note dated February 12, 2020 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due February 12, 2021-less unamortized debt discount of $34,644 and $ 0, respectively (i) 59,022 Convertible Promissory Note dated June 3, 2020 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due June 3, 2021-less unamortized debt discount of $31,438 and $ 0, respectively (i) 11,062 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $294,234, respectively (ii) - 74,566 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $90,054, respectively (ii) - 22,823 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $79,248, respectively (ii) - 20,084 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $9,005 respectively (ii) - 2,281 Convertible Promissory Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 6%, due February 12, 2020-less unamortized debt discount of $0 and $0, respectively (ii) - 25,587 Convertible Promissory Note dated January 27, 2020 payable to GW Holdings Group, LLC (“GWH”), interest at 6%, due January 27, 2021-less unamortized debt discount of $12,748 and $ 0 respectively (iii) 26,352 - Convertible Promissory Note dated June 1, 2020 payable to GW Holdings Group, LLC (“GWH”), interest at 6%, due June 1, 2021-less unamortized debt discount of $ 29,736 and $ 0 respectively (iv) 10,764 - Total $ 183,820 $ 399,318 (i) On February 12, 2019, (the “Issue Date”) the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. Eagle is to fund the $ 1,104,000 purchase price of the Eagle Note in tranches. The first tranche of $ 250,000 was received by the Company on February 13, 2019. The second tranche of $ 166,500 was received by the Company on January 17, 2020, the third tranche of $ 93,666 was received by the Company on February 12, 2020, and the fourth tranche of $ 42,500 was received by the Company on June 3, 2020. The loans are repayable one year from their respective funding dates and are convertible at the option of Eagle at a conversion price equal to 65% of the lowest closing price of the Company’s common stock for the preceding 15 trading days prior to the conversion date. Please see Note F-DERIVATIVE LIABILITY for further information. (ii) On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bore interest at 6%, were due on February 12, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new notes bore interest at 2%, were due on October 18, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY (iii) On January 27, 2020, the Company executed a Convertible Note (the “Convertible Note”) payable to GW Holdings Group, LLC, a New York limited liability company and its authorized successors and permitted assigns (“Holder”), the aggregate principal face amount of $166,500. The note bears interest at 6%, is due on January 27, 2021 and is convertible into common stock at a conversion price equal to 55% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY (iv) On June 1, 2020, the Company executed a Convertible Note (the “Convertible Note”) payable to GW Holdings Group, LLC, a New York limited liability company and its authorized successors and permitted assigns (“Holder”), the aggregate principal face amount of $ 40,500. The note bears interest at 6%, is due on June 1, 2021 and is convertible into common stock at a conversion price equal to 55% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY On May 26, 2020, the Company entered into a Surrender Agreement with Emet Capital Partners, LLC (“Emet”) pursuant to which Emet agreed to surrender its interests in the following convertible notes such notes in exchange for a payment of $70,000: 1. Convertible Redeemable Note issued on 10/18/19 in the amount of $3,128.79 2. Convertible Redeemable Note issued on 10/18/19 in the amount of $15,439.93 3. Convertible Redeemable Note issued on 10/18/19 in the amount of $7,018.15 4. Convertible Note issued on 10/18/19 in the amount of $451,504.95 5. Convertible Note issued on 10/18/19 in the amount of $112,876.28 6. Convertible Note issued on 10/18/19 in the amount of $99,331.13 7. Convertible Note issued on 10/18/19 in the amount of $11,287.65 The $472,170 excess of the $ 542,170 remaining amount of debt satisfied over the $ 70,000 cash payment was recognized as a gain in the three months ended June 30, 2020.

Derivative Liability

Derivative Liability	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	NOTE F - DERIVATIVE LIABILITY The derivative liability consists of: September 30, 2020 December 31, 2019 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i): Due February 12, 2020 $ - $ 182,625 Due January 27, 2021 94,481 - Due February 12, 2021 78,227 - Due June 3, 2021 41,099 Convertible Promissory Note dated January 27, 2020 payable to GW Holdings Group, LLC. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (iii) Due January 27, 2021 52,745 - Due June 1, 2021 59,383 - Convertible Promissory Notes dated October 18, 2019 payable to Emet. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (ii): $451,505 note due October 18, 2021 - 328,953 $112,876 note due October 18, 2021 - 100,680 $ 99,331 note due October 18, 2021 - 88,599 $ 11,288 note due October 18, 2021 - 10,068 $ 25,587 note due October 18, 2021 - 14,940 Total derivative liability $ 325,935 $ 725,865 The Convertible Promissory Notes (the “Notes”) contain a variable conversion feature based on the future trading price of the Company’s common stock. Therefore, the number of shares of common stock issuable upon conversion of the Notes is indeterminate. The fair value of the derivative liability was measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculation of the derivative liability of the Notes at September 30, 2020 were (1) stock price of $.0038 per share, (2) conversion prices ranging from $.0017 to $.0023 per share, (3) terms ranging from 119 days to 246 days, (4) expected volatility of 142.94%, and (5) risk free interest rates ranging from .10% to .11%. Assumptions used for the calculations of the derivative liability of the Notes at December 31, 2019 were (1) stock price of $ .0330 per share, (2) conversion prices ranging from $ .01885 to $ .02175 per share, (3) terms ranging from 43 days to 293 days, (4) expected volatility of 142,94%, and (5) risk free interest rates ranging from 1.50% to 1.60%.

Capital Stock and Warrants

Capital Stock and Warrants	9 Months Ended
	Sep. 30, 2020
Capital Stock And Warrants
Capital Stock and Warrants	NOTE G - CAPITAL STOCK AND WARRANTS Preferred Stock On July 31, 2018, The Greater Cannabis Company, Inc. (the “Company”) acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock. On February 14, 2019, the Company issued 9,000,000 shares of Series B Convertible Preferred Stock to Emet Capital Partners, LLC (“Emet”) in exchange for the surrender of all outstanding warrants held by Emet. Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $ 0.075 per share. On October 18, 2019, this exchange agreement was reversed. On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bore interest at 6%, were due on February 12, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new notes bore interest at 2%, were due on October 18, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. On May 26, 2020, the Company satisfied the 7 convertible notes payable to Emet in connection with a Surrender Agreement (see Note E). Common Stock Effective March 10, 2017, in connection with a partial spin-off of the Company from Sylios Corp, the Company issued a total of 26,905,969 shares of its common stock. 5,378,476 shares were issued to Sylios Corp (representing 19.99% of the issued and outstanding shares of Company common stock after the spin-off) and 21,527,493 shares were issued to the stockholders of record of Sylios Corp on February 3, 2017 on the basis of one share of Company common stock for each 500 shares of Sylios Corp common stock held (representing 80.01% of the issued and outstanding shares of Company common stock after the spin-off). On September 19, 2018, the Company issued 1,465,523 shares of its common stock pursuant to a conversion of $32,000 principal and $ 4,638 accrued interest of its convertible note dated May 25, 2017 by Emet Capital Partners, LLC. The $510,149 excess of the $ 546,787 fair value of the 1,465,523 shares over the $36,638 liability reduction was charged to Loss on Conversion of Debt. On October 26, 2018, the Company issued 1,034,477 shares of its common stock pursuant to a conversion of $30,531 principal and $ 503 accrued interest of its convertible note dated May 25, 2017 by Emet Capital Partners, LLC. The $ 82,758 excess of the $ 113,792 fair value of the 1,034,479 shares over the $ 31,034 liability reduction was charged to Loss on Conversion of Debt. On January 4, 2019, the Company issued 769,785 shares of its common stock pursuant to a conversion of $670 principal and $100 accrued interest of its convertible note dated May 25, 2018 by Emet Capital Partners, LLC (“Emet”). This conversion was based on a conversion price of $ 0.001 per share (rather than the Variable Conversion Price provided in the related note) submitted by Emet in its Conversion Notice. Emet asserted that the Company had committed a dilutive issuance, which triggered the “ratchet-down” provision of the related note which provides for a reduction of the conversion price. The Company has notified Emet that it disagrees with Emet’s assertion that a ratch-down dilutive issuance occurred. The $ 99,302 excess of the $100,072 fair value of the 769,785 shares over the $ 770 liability reduction was charged to Loss on Conversion of Debt in the three months ended June 30, 2020. On January 4, 2019, the Company issued 695,129 shares of its common stock pursuant to an exercise of the equivalent of 1,400 warrants (of the 440,000 warrants issued to Emet Capital Partners, LLC on May 25, 2017) in a cashless exercise transaction based on a ratchet-down exercise price of $ 0.001 per share. On April 16, 2019, the Company issued 1,384,600 shares of its common stock pursuant to conversions of $ 40,500 principal and $ 7,961 accrued interest of two convertible notes issued to by Emet Capital Partners, LLC (“Emet”). The $131,537 excess of the $179,998 fair value of the 1,384,600 shares over the $47,961 liability reduction was charged to Loss on Conversion of Debt in the three months ended June 30, 2019. On May 29, 2019, the Company issued a total of 542,000 shares of its common stock to two consulting firm entities for certain specified investor relations and advisory services. The $75,880 fair value of the 542,000 shares was charged to Other Operating Expenses in the three months ended June 30, 2019. On August 15, 2019, the Company issued 175,000 shares of its common stock to an entity consultant for accounting services rendered. The $12,250 fair value of the 175,000 shares was charged to Other Operating Expenses. On November 11, 2019, the Company issued 1,748,363 shares of its common stock pursuant to a conversion of $53,705 principal and $2,680 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 20, 2019, the Company issued 1,468,204 shares of its common stock pursuant to a conversion of $29,000 principal and $4,015 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 24, 2019, the Company issued 637,273 shares of its common stock pursuant to a conversion of $10,000 principal and $515 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. During the three months ended March 31, 2020, the Company issued a total of 21,484,688 shares of common stock pursuant to conversions of an aggregate of $165,350 in principal and $11,793 in interest under our outstanding convertible notes. The $228,949 excess of the $406,093 fair value of the 21,484,688 shares of common stock at the respective dates of issuance over the $177,143 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended June 30, 2020, the Company issued a total of 27,563,525 shares of common stock pursuant to conversions of an aggregate of $67,082 in principal and $10,613 in interest under our outstanding convertible notes. The $132,838 excess of the $210,532 fair value of the 27,563,525 shares of common stock at the respective dates of issuance over the $77,695 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended September 30, 2020, the Company issued a total of 115,277,834 shares of common stock pursuant to conversions of an aggregate of $311,050 in principal and $18,462 in interest under our outstanding convertible notes. The $467,554 excess of the $797,067 fair value of the 115,277,834 shares of common stock at the respective dates of issuance over the $329,512 liability reduction was charged to Loss on Conversions of Notes Payable. Warrants On February 14, 2019, the Company entered into an exchange agreement with Emet Capital Partners, LLC (“Emet”) pursuant to which the Company issued Emet 9,000,000 shares of its Series B Convertible Preferred Stock (the “Series B Preferred Shares”) in exchange for the surrender of all outstanding warrants held by Emet. Each Series B Preferred Share was convertible into one share of the Company’s common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company’s common stock was less than $0.075. In such case, Emet was to receive an additional number of shares of common stock equal to the number of shares being converted divided by the applicable market price. On October 18, 2019, this exchange agreement was reversed and the warrants were exchanged for four new convertible notes payable to Emet in the total amount of $ 675,000. See Preferred Stock above. At the date hereof, the Company has no outstanding warrants.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE H - INCOME TAXES The Company and its United States subsidiaries expect to file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, will file Canada and Ontario income tax returns. At September 30, 2020 the Company has available for federal income tax purposes a net operating loss carry forward that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is not more likely than not that the benefits will be realized. Due to significant changes in the Company’s ownership, the future use of its existing net operating losses will be limited. All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service.

Note Receivable

Note Receivable	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Note Receivable	NOTE I – NOTE RECEIVABLE On June 10, 2020, in anticipation of developing a CBD business with Koltuv Ventures, LLC (the “Borrower”) (see Note C), the Company agreed to lend the Borrower USD $50,000 to be repaid either (a) out of available cash as soon as practicable, including from sales of Bob Ross cosmetic products, or (b) on the date that is 18 months from the date thereof, whichever is earlier (the “Maturity Date”). The Loan shall not bear interest except to the extent that any part of the Loan remains outstanding as at the Maturity Date, in which case the following sentence applies. From the date after the Maturity Date and onward, the outstanding principal amount of the Loan shall bear interest at a rate of 2% per annum. Any payment of cash to be made by Borrower to Lender shall be applied first to outstanding principal and second to any accrued, but unpaid, interest. As of September 30, 2020, the balance of the note was $ 23,575.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE J - COMMITMENTS AND CONTINGENCIES Pharmedica Exclusive License Agreement On June 21, 2018, Green C executed an Exclusive License Agreement with Pharmedica, Ltd. (“Pharmedica”), an Israeli company, to exploit certain Pharmedica intellectual property for the development and distribution of a certain Licensed Product involved in the transmucosal delivery of medicinal or recreational cannabis. The agreement provides for Green C payments to Pharmedica of a $100,000 license fee (which was paid by 2591028 Ontario Limited, an entity affiliated with Green C’s Chief Executive Officer, on June 26, 2018) and annual royalties at a rate of 5% of the Net Sales of the Licensed Product subject to a Minimum Annual Royalty of $50,000. The agreement also provides for certain milestones to be accomplished by Green C in order for Green C to retain the license. Green C and Pharmedica each may terminate the agreement upon the occurrence of a material breach by the other party of its obligations under the agreement and such other party’s failure to remedy such breach to the reasonable satisfaction of the other party within thirty (30) days after being requested in writing to do so. The Company generated only minimal revenues from this asset through December 31, 2019 and did not pay the Year 1 Minimum Annual Royalty of $50,000 due Pharmedica. Accordingly, we recorded an impairment charge of $69,749 at December 31, 2019 and reduced the $69,749 remaining carrying value of this intangible asset to $0. On September 2, 2020, Green C notified Pharmedica of Green C’s termination of the Exclusive License Agreement and Green C’s intention to wind up Green C. On September 17, 2020, Pharmedica notified Green C of Pharmedica’s acceptance of Green C’s proposal to terminate the license agreement and Pharmedica’s intention not to burden Green C further. Accordingly, we recorded “Forgiveness of Royalty Payable” other income of $50,000 in the three months ended September 30, 2020 and reduced the $50,000 “Accrued Royalties” liability balance to $0. Sub-License Agreement with Symtomax Unipessoal Lda On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”). The agreement provides for the Company’s grant to Symtomax of a non-exclusive right and sub-license to use certain Company technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa. The agreement provides for Symtomax payments of royalties to the Company (payable monthly) ranging from 10% to 17% of Symtomax sales of eluting patches developed from Company technology. On May 27, 2020, the Company executed an amended and restated sub-license agreement with Symtomax (the “Amended License Agreement”). The term of the Amended License Agreement ends the earlier of (i) August 31, 2021 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year. To date, Symtomax has not made any sales requiring the payment of royalties to the Company. Service Agreements On July 31, 2018, the Company executed Services Agreements with its newly appointed Chief Executive Officer (the “CEO”) and its newly appointed Chief Legal Officer (the “CLO”), for terms of five years. The Agreements provide for a monthly base salary of $10,000 for the CEO and a monthly base salary of $7,000 for the CLO. For the three months ended September 30, 2020 and 2019, the Company expensed a total of $30,000 and $21,000, respectively, as officer compensation pursuant to these agreements. Sales Concentration One customer accounted for 100% of sales in the nine months ended eptember 30, 2020.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE K – SUBSEQUENT EVENTS From October 1, 2020 to November 6, 2020, the Company issued a total of 102,627,451 shares of its common stock to 2 lenders pursuant to conversions totaling $ 156,838 principal and $ 8,649 accrued interest. The $ 178,460 excess of the $ 343,947 fair value of the 102,627,451 shares of our common stock at the respective dates of issuance over the $165,487 debt satisfied will be recognized as a loss in the three months ended December 31, 2020.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately 94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). The Company’s business plan is to (i) commercialize its ETP technology and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiaries Green C Corporation and Biocanrx Inc.
Interim Financial Statements	Interim Financial Statements The interim financial statements as of September 30, 2020 and for the three and nne months ended September 30, 2020 and 2019 are unaudited and have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. These statements reflect all normal and recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the information contained herein. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of results that may be expected for the year ending December 31, 2020. Certain information and finance disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2019 as included in our report on Form 10-K.
Cash and Cash Equivalents	Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no cash equivalents.
Income Taxes	Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of September 30, 2020, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Financial Instruments and Fair Value of Financial Instruments	Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods.
Derivative Liabilities	Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.
Long-lived Assets	Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
Equity Instruments Issued to Non-employees for Acquiring Goods or Services	Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values.
Related Parties	Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party.
Revenue Recognition	Revenue Recognition Revenue from product sales will be recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) the price is fixed or determinable, (3) collectability is reasonably assured, and (4) delivery has occurred.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.
Loss Per Share	Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note G), shares relating to convertible notes payable to third parties (Please see NOTE E - NOTES PAYABLE TO THIRD PARTIES see NOTE G - CAPITAL STOCK AND WARRANTS
Recently Enacted Accounting Standards	Recently Enacted Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all prior revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under prior U.S. GAAP. As amended by the FASB in July 2015, the standard became effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 has had no impact on our Financial statements for the periods presented. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-08 has had no impact on our Financial statements for the periods presentd. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-10 has had no impact on our financial statements for the periods presented. On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance became effective for annual periods beginning after December 15, 2018. Accordingly, effective January 1, 2019, the Company reduced the derivative liability of warrants with “down round” features (and do not contain variable conversion features) of $108,427 at December 31, 2018 to $0 and recognized a $108,427 cumulative effect adjustment reduction of accumulated deficit.

Loans Payable to Related Part_2

Loans Payable to Related Parties (Tables)	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Schedule of Loans Payable to Related Parties	Loans payable to related parties consist of: September 30, December 31, Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock 80,000 80,000 Total $ 260,000 $ 260,000

Notes Payable to Third Parties

Notes Payable to Third Parties (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Notes Payable to Third Parties	Notes payable to third parties consist of: September 30, 2020 December 31, 2019 Allonge to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 $ - $ 2,420 Allonge 2 to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 - 1,100 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share. 375 375 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due February 12, 2020-less unamortized debt discount of $ 0 and $ 33,396, respectively (i) - 250,082 Convertible Promissory Note dated January 27, 2020 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due January 27, 2021-less unamortized debt discount of $36,883 and $ 0, respectively (i) 76,245 - Convertible Promissory Note dated February 12, 2020 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due February 12, 2021-less unamortized debt discount of $34,644 and $ 0, respectively (i) 59,022 Convertible Promissory Note dated June 3, 2020 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due June 3, 2021-less unamortized debt discount of $31,438 and $ 0, respectively (i) 11,062 - Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $294,234, respectively (ii) - 74,566 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $90,054, respectively (ii) - 22,823 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $79,248, respectively (ii) - 20,084 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $9,005 respectively (ii) - 2,281 Convertible Promissory Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 6%, due February 12, 2020-less unamortized debt discount of $0 and $0, respectively (ii) - 25,587 Convertible Promissory Note dated January 27, 2020 payable to GW Holdings Group, LLC (“GWH”), interest at 6%, due January 27, 2021-less unamortized debt discount of $12,748 and $ 0 respectively (iii) 26,352 - Convertible Promissory Note dated June 1, 2020 payable to GW Holdings Group, LLC (“GWH”), interest at 6%, due June 1, 2021-less unamortized debt discount of $ 29,736 and $ 0 respectively (iv) 10,764 - Total $ 183,820 $ 399,318 (i) On February 12, 2019, (the “Issue Date”) the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. Eagle is to fund the $ 1,104,000 purchase price of the Eagle Note in tranches. The first tranche of $ 250,000 was received by the Company on February 13, 2019. The second tranche of $ 166,500 was received by the Company on January 17, 2020, the third tranche of $ 93,666 was received by the Company on February 12, 2020, and the fourth tranche of $ 42,500 was received by the Company on June 3, 2020. The loans are repayable one year from their respective funding dates and are convertible at the option of Eagle at a conversion price equal to 65% of the lowest closing price of the Company’s common stock for the preceding 15 trading days prior to the conversion date. Please see Note F-DERIVATIVE LIABILITY for further information. (ii) On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bore interest at 6%, were due on February 12, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new notes bore interest at 2%, were due on October 18, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY (iii) On January 27, 2020, the Company executed a Convertible Note (the “Convertible Note”) payable to GW Holdings Group, LLC, a New York limited liability company and its authorized successors and permitted assigns (“Holder”), the aggregate principal face amount of $166,500. The note bears interest at 6%, is due on January 27, 2021 and is convertible into common stock at a conversion price equal to 55% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY (iv) On June 1, 2020, the Company executed a Convertible Note (the “Convertible Note”) payable to GW Holdings Group, LLC, a New York limited liability company and its authorized successors and permitted assigns (“Holder”), the aggregate principal face amount of $ 40,500. The note bears interest at 6%, is due on June 1, 2021 and is convertible into common stock at a conversion price equal to 55% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY

Derivative Liability (Tables)

Derivative Liability (Tables)	9 Months Ended
	Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liability	The derivative liability consists of: September 30, 2020 December 31, 2019 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (i): Due February 12, 2020 $ - $ 182,625 Due January 27, 2021 94,481 - Due February 12, 2021 78,227 - Due June 3, 2021 41,099 Convertible Promissory Note dated January 27, 2020 payable to GW Holdings Group, LLC. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (iii) Due January 27, 2021 52,745 - Due June 1, 2021 59,383 - Convertible Promissory Notes dated October 18, 2019 payable to Emet. Please see NOTE E – NOTES PAYABLE TO THIRD PARTIES for further information (ii): $451,505 note due October 18, 2021 - 328,953 $112,876 note due October 18, 2021 - 100,680 $ 99,331 note due October 18, 2021 - 88,599 $ 11,288 note due October 18, 2021 - 10,068 $ 25,587 note due October 18, 2021 - 14,940 Total derivative liability $ 325,935 $ 725,865

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Jan. 04, 2019	Jul. 31, 2018	Mar. 10, 2017	Sep. 30, 2020	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Number of shares issued	695,129		26,905,969
Advertising costs
Derivative liability				$ 325,935	$ 725,865	$ 0	$ 108,427
Cumulative effect of accumulated deficit						$ 108,427
Series A Convertible Preferred Stock [Member]
Anti-dilutive shares excluded from computation				470,599,900
Green C Corporation [Member] | Former Share Holders [Member]
Percentage of issued and outstanding shares acquired		94.00%
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Number of shares issued		9,411,998
Conversion of convertible preferred stock		50
Common stock, voting rights		Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.
Green C Corporation [Member] | Class A Common Stock [Member]
Percentage of issued and outstanding shares acquired		100.00%
Common stock, voting rights		Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 178,632						$ 178,632		$ 24,662
Current liabilities	925,196						925,196
Working capital deficit	(722,989)						(722,989)
Net loss	$ (459,260)	$ 1,102,449	$ (1,211,569)	$ (126,430)	$ (287,779)	$ (138,349)	(568,380)	$ (552,558)
Net cash provided in operating activities							$ (260,698)	$ (264,043)

Right of First Refusal Agreem_2

Right of First Refusal Agreement (Details Narrative) - Right of First Refusal Agreement [Member] - KTV [Member]	Jan. 30, 2020USD ($)
Paid to related party	$ 25,000
CBD [Member]
CBD opportunities term	5 years

Loans Payable to Related Part_3

Loans Payable to Related Parties (Details Narrative)	Jul. 31, 2018USD ($)
Loan and Contribution Agreements [Member] | Maximum [Member]
Repayment of related party debt	$ 1,500,000

Loans Payable to Related Part_4

Loans Payable to Related Parties - Schedule of Loans Payable to Related Parties (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Total	$ 260,000	$ 260,000
Elisha Kalfa and Yonah Kalfa [Member]
Total	180,000	180,000
Fernando Bisker and Sigalush, LLC [Member]
Total	$ 80,000	$ 80,000

Loans Payable to Related Part_5

Loans Payable to Related Parties - Schedule of Loans Payable to Related Parties (Details) (Parenthetical) - Series A Convertible Preferred Stock [Member] - shares	Sep. 30, 2020	Dec. 31, 2019
Elisha Kalfa and Yonah Kalfa [Member]
Number of shares held by holders of preferred stock	2,966,666	2,966,666
Fernando Bisker and Sigalush, LLC [Member]
Number of shares held by holders of preferred stock	2,966,666	2,966,666

Notes Payable to Third Partie_2

Notes Payable to Third Parties (Details Narrative) - USD ($)	May 26, 2020	Jun. 30, 2020	Sep. 30, 2020	Mar. 31, 2020	Oct. 18, 2019	Apr. 16, 2019	Jan. 04, 2019
Payments for notes payable		$ 70,000
Notes payable		67,082	$ 311,050	$ 165,350		$ 40,500	$ 670
Notes payable excess amount		472,170
Remaining debt satisfied		$ 542,170
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member]
Payments for notes payable	$ 70,000
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Redeemable One [Member]
Notes payable					$ 3,129
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Redeemable Two [Member]
Notes payable					15,440
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Redeemable [Member]
Notes payable					7,018
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Note [Member]
Notes payable					451,505
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Note One [Member]
Notes payable					112,876
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Note Two [Member]
Notes payable					99,331
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Note Three [Member]
Notes payable					$ 11,288

Notes Payable to Third Partie_3

Notes Payable to Third Parties - Schedule of Notes Payable to Third Parties (Details) - USD ($)		Sep. 30, 2020	Dec. 31, 2019
Notes payable to third parties, total		$ 183,820	$ 399,318
Convertible Promissory Note One [Member]
Notes payable to third parties, total			2,420
Convertible Promissory Note Two [Member]
Notes payable to third parties, total			1,100
Promissory Note [Member]
Notes payable to third parties, total		375	375
Convertible Promissory Note Three [Member]
Notes payable to third parties, total	[1]		250,082
Convertible Promissory Note Four [Member]
Notes payable to third parties, total	[1]	76,245
Convertible Promissory Note Five [Member]
Notes payable to third parties, total	[1]	59,022
Convertible Promissory Note Six [Member]
Notes payable to third parties, total	[1]	11,062
Convertible Warrant Note One [Member]
Notes payable to third parties, total	[2]		74,566
Convertible Warrant Notes Two [Member]
Notes payable to third parties, total	[2]		22,823
Convertible Warrant Notes Three [Member]
Notes payable to third parties, total	[2]		20,084
Convertible Warrant Notes Four [Member]
Notes payable to third parties, total	[2]		2,281
Convertible Promissory Note Seven [Member]
Notes payable to third parties, total	[2]		25,587
Convertible Promissory Note Eight [Member]
Notes payable to third parties, total	[3]	26,352
Convertible Promissory Note Nine [Member]
Notes payable to third parties, total	[4]	$ 10,764
[1]	On February 12, 2019, (the "Issue Date") the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC ("Eagle"), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the "Eagle Note"). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. Eagle is to fund the $ 1,104,000 purchase price of the Eagle Note in tranches. The first tranche of $ 250,000 was received by the Company on February 13, 2019. The second tranche of $ 166,500 was received by the Company on January 17, 2020, the third tranche of $ 93,666 was received by the Company on February 12, 2020, and the fourth tranche of $ 42,500 was received by the Company on June 3, 2020. The loans are repayable one year from their respective funding dates and are convertible at the option of Eagle at a conversion price equal to 65% of the lowest closing price of the Company's common stock for the preceding 15 trading days prior to the conversion date. Please see Note F-DERIVATIVE LIABILITY for further information.
[2]	On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (Emet). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bore interest at 6%, were due on February 12, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new notes bore interest at 2%, were due on October 18, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY for further information.
[3]	On January 27, 2020, the Company executed a Convertible Note (the "Convertible Note") payable to GW Holdings Group, LLC, a New York limited liability company and its authorized successors and permitted assigns ("Holder"), the aggregate principal face amount of $166,500. The note bears interest at 6%, is due on January 27, 2021 and is convertible into common stock at a conversion price equal to 55% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY for further information.
[4]	On June 1, 2020, the Company executed a Convertible Note (the "Convertible Note") payable to GW Holdings Group, LLC, a New York limited liability company and its authorized successors and permitted assigns ("Holder"), the aggregate principal face amount of $ 40,500. The note bears interest at 6%, is due on June 1, 2021 and is convertible into common stock at a conversion price equal to 55% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. Please see NOTE F - DERIVATIVE LIABILITY for further information.

Notes Payable to Third Partie_4

Notes Payable to Third Parties - Schedule of Notes Payable to Third Parties (Details) (Parenthetical)

Jun. 03, 2020USD ($)

Jun. 01, 2020USD ($)Integer

Feb. 12, 2020USD ($)

Jan. 27, 2020USD ($)Integer

Jan. 17, 2020USD ($)

Dec. 24, 2019USD ($)shares

Dec. 20, 2019USD ($)shares

Nov. 11, 2019USD ($)shares

Oct. 18, 2019USD ($)Integer

Apr. 16, 2019USD ($)shares

Feb. 14, 2019shares

Feb. 13, 2019USD ($)

Feb. 12, 2019USD ($)

Jan. 04, 2019USD ($)shares

Sep. 14, 2017

Mar. 28, 2017$ / shares

Sep. 30, 2020USD ($)shares

Jun. 30, 2020USD ($)shares

Mar. 31, 2020USD ($)shares

Sep. 30, 2020USD ($)Integer

Dec. 31, 2019USD ($)

Debt instrument, principal amount

$ 311,050

$ 67,082

$ 165,350

$ 311,050

Accrued interest

$ 515

$ 4,015

$ 2,680

$ 7,961

$ 100

$ 18,462

$ 10,613

$ 11,793

18,462

Debt conversion converted shares issued | shares

637,273

1,468,204

1,748,363

1,384,600

769,785

115,277,834

27,563,525

21,484,688

Allonge [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

5.00%

Debt instrument, maturity date

Sep. 14, 2018

Allonge 2 [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

5.00%

Debt instrument, maturity date

Sep. 14, 2018

Promissory Note [Member] | John T. Root [Member]

Debt instrument, interest rate

4.00%

Debt instrument, maturity date

Sep. 28, 2017

Conversion price | $ / shares

$ 0.001

Convertible Promissory Note One [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Oct. 18, 2021

Debt instrument, principal amount

$ 1,200,000

Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member]

Debt instrument, maturity date

Feb. 12, 2020

Unamortized debt discount

$ 0

$ 0

$ 33,396

Debt conversion, original issue discount

$ 96,000

Funding value of issuance of note

$ 1,104,000

Trading days percentage

65.00%

Trading days period | Integer

15

Debt instrument, term

1 year

Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member] | First Tranche [Member]

Proceeds from issuance of convertible debt

$ 250,000

Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member] | Second Tranche [Member]

Proceeds from issuance of convertible debt

$ 166,500

Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member] | Third Tranche [Member]

Proceeds from issuance of convertible debt

$ 93,666

Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member] | Four Tranche [Member]

Proceeds from issuance of convertible debt

$ 42,500

Convertible Promissory Note One [Member] | GW Holdings Group, LLC [Member]

Debt instrument, maturity date

Jan. 27, 2021

Convertible Promissory Note Two [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, maturity date

Oct. 18, 2021

Convertible Promissory Note Two [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Jan. 27, 2021

Jan. 27, 2021

Unamortized debt discount

36,883

$ 36,883

0

Convertible Promissory Note Two [Member] | GW Holdings Group, LLC [Member]

Debt instrument, maturity date

Jun. 1, 2021

Convertible Promissory Note Three [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, maturity date

Oct. 18, 2021

Convertible Promissory Note Three [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Feb. 12, 2020

Feb. 12, 2021

Unamortized debt discount

34,644

34,644

0

Convertible Promissory Note Six [Member] | Eagle Equities, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Jun. 3, 2021

Unamortized debt discount

31,438

31,438

0

Convertible Warrant Note One [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Unamortized debt discount

0

0

294,234

Debt conversion converted shares issued | shares

9,000,000

Convertible Warrant Note One [Member] | Emet Capital Partners, LLC [Member] | First Exchange Agreement [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Feb. 12, 2020

Debt instrument, principal amount

$ 20,399

Trading days percentage

75.00%

Trading days period | Integer

15

Accrued interest

$ 5,189

Debt instrument, periodic payment

$ 25,587

Four New Convertible Warrant Notes [Member] | Emet Capital Partners, LLC [Member] | Second Exchange Agreement [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Trading days percentage

75.00%

Trading days period | Integer

15

Debt instrument, periodic payment

$ 675,000

Convertible Warrant Notes Two [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Unamortized debt discount

0

0

90,054

Convertible Warrant Notes Three [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Unamortized debt discount

0

0

79,248

Convertible Warrant Notes Four [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

2.00%

Debt instrument, maturity date

Oct. 18, 2020

Unamortized debt discount

0

0

9,005

Convertible Promissory Note Four [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Oct. 18, 2020

Unamortized debt discount

0

0

0

Convertible Promissory Note Four [Member] | Eagle Equities, LLC [Member]

Debt instrument, maturity date

Jun. 3, 2021

Convertible Promissory Note Five [Member] | Emet Capital Partners, LLC [Member]

Debt instrument, maturity date

Oct. 18, 2021

Unamortized debt discount

128,721

128,721

0

Convertible Promissory Note Five [Member] | GW Holdings Group, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Jan. 27, 2021

Debt instrument, principal amount

$ 166,500

Trading days percentage

55.00%

Trading days period | Integer

15

Convertible Promissory Note Seven [Member] | GW Holdings Group, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Jun. 1, 2021

Unamortized debt discount

40,389

40,389

0

Debt instrument, principal amount

$ 40,500

Trading days percentage

55.00%

Trading days period | Integer

15

Convertible Promissory Note Eight [Member] | GW Holdings Group, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Jan. 27, 2021

Unamortized debt discount

12,748

12,748

0

Convertible Promissory Note Nine [Member] | GW Holdings Group, LLC [Member]

Debt instrument, interest rate

6.00%

Debt instrument, maturity date

Jun. 1, 2021

Unamortized debt discount

$ 29,736

$ 29,736

$ 0

Derivative Liability (Details N

Derivative Liability (Details Narrative) - Convertible Promissory Notes [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2020$ / shares	Dec. 31, 2019$ / shares
Fair value of assumption stock price	$ 0.0038	$ .0330
Measurement Input, Exercise Price [Member] | Minimum [Member]
Derivative liability measurement input	.0017	0.01885
Measurement Input, Exercise Price [Member] | Maximum [Member]
Derivative liability measurement input	.0023	0.02175
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair value of assumption term	246 days	293 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair value of assumption term	119 days	43 days
Measurement Input, Price Volatility [Member]
Derivative liability measurement input	142.94	142.94
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Derivative liability measurement input	10	1.50
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Derivative liability measurement input	11	1.60

Derivative Liability - Schedule

Derivative Liability - Schedule of Derivative Liability (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Total derivative liability	$ 325,935	$ 725,865	$ 0	$ 108,427
Convertible Promissory Notes One [Member]
Total derivative liability		182,625
Convertible Promissory Notes Two [Member]
Total derivative liability	94,481
Convertible Promissory Notes Three [Member]
Total derivative liability	78,227
Convertible Promissory Notes Four [Member]
Total derivative liability	41,099
Convertible Promissory Notes Five [Member]
Total derivative liability	52,745
Convertible Promissory Notes Six [Member]
Total derivative liability	59,383
Convertible Promissory Note Seven [Member]
Total derivative liability		328,953
Convertible Promissory Note Eight [Member]
Total derivative liability		100,680
Convertible Promissory Note Nine [Member]
Total derivative liability		88,599
Convertible Promissory Note Ten [Member]
Total derivative liability		10,068
Convertible Promissory Note Eleven [Member]
Total derivative liability		$ 14,940

Derivative Liability - Schedu_2

Derivative Liability - Schedule of Derivative Liability (Details) (Parenthetical) - USD ($)	Feb. 12, 2020	Jan. 27, 2020	Oct. 18, 2019	Feb. 12, 2019
Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member]
Debt instrument, maturity date				Feb. 12, 2020
Convertible Promissory Note One [Member] | GW Holdings Group, LLC [Member]
Debt instrument, maturity date		Jan. 27, 2021
Convertible Promissory Note One [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date			Oct. 18, 2021
Notes payable to related parties			$ 451,505
Convertible Promissory Note Two [Member] | Eagle Equities, LLC [Member]
Debt instrument, maturity date		Jan. 27, 2021		Jan. 27, 2021
Convertible Promissory Note Two [Member] | GW Holdings Group, LLC [Member]
Debt instrument, maturity date		Jun. 1, 2021
Convertible Promissory Note Two [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date			Oct. 18, 2021
Notes payable to related parties			$ 112,876
Convertible Promissory Note Three [Member] | Eagle Equities, LLC [Member]
Debt instrument, maturity date	Feb. 12, 2020			Feb. 12, 2021
Convertible Promissory Note Three [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date			Oct. 18, 2021
Notes payable to related parties			$ 99,331
Convertible Promissory Note Four [Member] | Eagle Equities, LLC [Member]
Debt instrument, maturity date				Jun. 3, 2021
Convertible Promissory Note Four [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date			Oct. 18, 2020
Notes payable to related parties			$ 11,288
Convertible Promissory Note Five [Member] | GW Holdings Group, LLC [Member]
Debt instrument, maturity date		Jan. 27, 2021
Convertible Promissory Note Five [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date			Oct. 18, 2021
Notes payable to related parties			$ 25,587

Capital Stock and Warrants (Det

Capital Stock and Warrants (Details Narrative)	Dec. 24, 2019USD ($)shares	Dec. 20, 2019USD ($)shares	Nov. 11, 2019USD ($)shares	Oct. 18, 2019USD ($)Integer	Aug. 15, 2019USD ($)shares	May 29, 2019shares	Apr. 16, 2019USD ($)shares	Feb. 14, 2019$ / sharesshares	Jan. 04, 2019USD ($)$ / sharesshares	Jan. 04, 2019USD ($)$ / sharesshares	Oct. 26, 2018USD ($)shares	Sep. 19, 2018USD ($)shares	Jul. 31, 2018shares	Mar. 10, 2017shares	Feb. 03, 2017shares	Sep. 30, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Sep. 30, 2019USD ($)shares	Jun. 30, 2019USD ($)shares	Sep. 30, 2020USD ($)shares	Sep. 30, 2019USD ($)shares	May 25, 2017shares
Number of shares issued during the period, shares										695,129				26,905,969
Debt instrument, principal amount | $																$ 311,050	$ 67,082	$ 165,350			$ 311,050
Accrued interest | $	$ 515	$ 4,015	$ 2,680				$ 7,961		$ 100	$ 100						$ 18,462	$ 10,613	$ 11,793			18,462
Debt conversion converted shares issued	637,273	1,468,204	1,748,363				1,384,600			769,785						115,277,834	27,563,525	21,484,688
Number of stock value issued for debt conversion | $	$ 10,000	$ 29,000	$ 53,705				$ 179,998			$ 100,072						$ 797,067	$ 210,532	$ 406,093
Loss on conversion of debt | $																(467,555)			$ 24,035		(829,342)	$ (230,839)
Number of shares issued for services																				542,000
Value of shares issued for services | $																				$ 75,880
Excess of fair value | $																467,554	132,838	228,949
Liability reduction | $																$ 77,695	$ 77,695	$ 177,143			$ 77,695
Warrants to purchase common stock									1,400	1,400
Two Consulting Firm Entities [Member]
Number of shares issued for services						542,000
Investor Relations And Advisory Services [Member] | Common Stock [Member]
Number of shares issued for services																				542,000
Convertible Warrant Note One [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate				2.00%
Debt instrument, maturity date				Oct. 18, 2020
Debt conversion converted shares issued								9,000,000
Convertible Warrant Note One [Member] | Emet Capital Partners, LLC [Member] | First Exchange Agreement [Member]
Debt instrument, principal amount | $				$ 20,399
Accrued interest | $				5,189
Debt instrument, periodic payment | $				$ 25,587
Debt instrument, interest rate				6.00%
Debt instrument, maturity date				Feb. 12, 2020
Trading days percentage				75.00%
Trading days period | Integer				15
Four New Convertible Warrant Notes [Member] | Emet Capital Partners, LLC [Member] | Second Exchange Agreement [Member]
Debt instrument, periodic payment | $				$ 675,000
Debt instrument, interest rate				2.00%
Debt instrument, maturity date				Oct. 18, 2020
Trading days percentage				75.00%
Trading days period | Integer				15
Four New Convertible Warrant Notes [Member] | Emet Capital Partners, LLC [Member] | Exchange Agreement [Member]
Debt instrument, periodic payment | $				$ 675,000
Emet Capital Partners, LLC [Member]
Number of shares issued during the period, shares							1,384,600		695,129
Conversion price | $ / shares									$ 0.001	$ 0.001
Debt instrument, principal amount | $							$ 40,500		$ 670	$ 670
Accrued interest | $							$ 7,961		$ 100	$ 100	$ 503	$ 4,638
Debt conversion converted shares issued									769,785		1,034,477	1,465,523										769,785
Number of stock value issued for debt conversion | $											$ 30,531	$ 32,000
Excess of common stock value | $											82,758	510,149							131,537			$ 99,302
Fair value of common stock | $					$ 12,250						$ 113,792	$ 546,787							$ 179,998			$ 100,072
Excess of common stock, shares											1,034,479	1,465,523							1,384,600			1,384,600
Loss on conversion of debt | $											$ 31,034	$ 36,638							$ 47,961			$ 770
Warrant exercise price | $ / shares								$ 0.075	$ 0.001	$ 0.001
Number of warrant issued									1,400	1,400													440,000
Number of shares issued for services					175,000
Warrants to purchase common stock								9,000,000
Number of warrant outstanding
Sylios Corp [Member]
Ownership percentage														19.99%	80.01%
Number of shares issued during the period, shares														5,378,476	21,527,493
Common stock, shares held															500
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Number of shares issued during the period, shares													9,411,998
Number of common stock converted													50
Common stock, voting rights													Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.
Series B Convertible Preferred Stock [Member] | Emet Capital Partners, LLC [Member]
Number of shares issued during the period, shares								9,000,000
Conversion price | $ / shares								$ 0.075
Preferred stock conversion basis, description								Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $ 0.075 per share.
Green C Corporation [Member] | Class A Common Stock [Member]
Ownership percentage													100.00%
Common stock, voting rights													Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)	Jun. 10, 2020	Sep. 30, 2020	Dec. 31, 2019
Notes receivable		$ 23,575
Koltuv Ventures, LLC [Member]
Repayment of notes receivable	$ 50,000
Interest rate	2.00%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Jul. 15, 2019	Jul. 31, 2018	Jun. 26, 2018	Jun. 21, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Forgiveness of royalty payable					$ 50,000		$ 50,000
Officers compensation					51,000	$ 51,000	153,000	153,000
Pharmedica, Ltd. [Member]
Minimum annual royalty amount							50,000
Impairment charge							69,749
Reduction of carrying value of assets									$ 69,749
Intangible assets									$ 0
Exclusive License Agreement [Member] | Green C's Corporation [Member]
License fee				$ 100,000
Annual royalties rate			5.00%
Minimum annual royalty amount			$ 50,000
Forgiveness of royalty payable							50,000
Reduction of accrued royalties							50,000
Accrued royalties					$ 0		0
Sub-License Agreement [Member] | Symtomax Unipessoal Lda [Member] | Minimum [Member]
Annual royalties rate	10.00%
Sub-License Agreement [Member] | Symtomax Unipessoal Lda [Member] | Maximum [Member]
Annual royalties rate	17.00%
Royalty payment	$ 1,000,000
Services Agreements [Member]
Officers compensation							$ 30,000	$ 21,000
Services Agreements [Member] | Chief Executive Officer [Member]
Agreement terms		5 years
Officers compensation		$ 10,000
Services Agreements [Member] | Chief Legal Officer [Member]
Officers compensation		$ 7,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Apr. 16, 2019	Jan. 04, 2019	Nov. 06, 2020	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Debt conversion converted shares issued	637,273	1,468,204	1,748,363	1,384,600	769,785			115,277,834	27,563,525	21,484,688
Debt principal amount								$ 311,050	$ 67,082	$ 165,350
Convertible Notes [Member] | Forecast [Member]
Loss on debt satisfied amount							$ 165,487
Convertible Notes [Member] | Subsequent Event [Member]
Fair value of debt						$ 178,460
Excess of debt fair value						$ 343,947
Convertible Notes [Member] | 2 Lenders [Member] | Subsequent Event [Member]
Debt conversion converted shares issued						102,627,451
Debt principal amount						$ 156,838
Accrued interest						$ 8,649